Kaposi sarcoma herpesvirus-associated cancers and related diseases.
This review discusses the pathogenesis and recent advances in the management of Kaposi sarcoma herpesvirus (KSHV)-associated diseases.



KSHV, a gammaherpesvirus, causes several tumors and related diseases, including Kaposi sarcoma, a form of multicentric Castleman disease (KSHV-MCD), and primary effusion lymphoma. These most often develop in patients infected with human immunodeficiency virus (HIV). KSHV inflammatory cytokine syndrome (KICS) is a newly described syndrome with high mortality that has inflammatory symptoms-like MCD but not the pathologic lymph node findings. KSHV-associated diseases are often associated with dysregulated human interleukin-6, and KSHV encodes a viral interleukin-6, both of which contribute to disease pathogenesis. Treatment of HIV is important in HIV-infected patients. Strategies to prevent KSHV infection may reduce the incidence of these tumors. Pomalidomide, an immunomodulatory agent, has activity in Kaposi sarcoma. Rituximab is active in KSHV-MCD but can cause Kaposi sarcoma exacerbation; rituximab plus liposomal doxorubicin is useful to treat KSHV-MCD patients with concurrent Kaposi sarcoma.



KSHV is the etiological agents of all forms of Kaposi sarcoma and several other diseases. Strategies employing immunomodulatory agents, cytokine inhibition, and targeting of KSHV-infected cells are areas of active research.
HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
Priscila H
PH
Goncalves
Joseph
J
Ziegelbauer
Thomas S
TS
Uldrick
Robert
R
Yarchoan
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005871:Castleman Disease / Q000628:therapy* / Q000821:virology; D019288:Herpesvirus 8, Human / Q000472:pathogenicity; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D054685:Lymphoma, Primary Effusion / Q000628:therapy* / Q000821:virology; D012514:Sarcoma, Kaposi / Q000628:therapy* / Q000821:virology
D000970:Antineoplastic Agents; D007155:Immunologic Factors
Blood. 1999 Jun 15;93(12):4034-43
10361100
Blood. 1999 Jun 15;93(12):4044-58
10361101
Virology. 1999 Nov 25;264(2):254-64
10562490
Nature. 1999 Dec 23-30;402(6764):889-94
10622254
Am J Epidemiol. 2000 Feb 1;151(3):213-24
10670545
J Clin Oncol. 2000 Apr;18(7):1550-7
10735904
Blood. 2000 Sep 15;96(6):2069-73
10979949
Blood. 2000 Oct 1;96(7):2537-42
11001908
N Engl J Med. 2000 Nov 9;343(19):1369-77
11070101
Br J Haematol. 2000 Oct;111(1):247-57
11091208
J Virol. 2001 Jan;75(1):429-38
11119611
Blood. 2001 Feb 1;97(3):744-51
11157493
Blood. 2001 May 15;97(10):3244-50
11342455
J Clin Oncol. 2002 Jan 1;20(1):153-9
11773164
J Acquir Immune Defic Syndr. 2002 Apr 1;29(4):418-21
11917248
J Interferon Cytokine Res. 2002 Mar;22(3):295-303
12034036
Cancer. 2002 Jul 1;95(1):147-54
12115328
J Clin Oncol. 2002 Aug 1;20(15):3236-41
12149296
Oncogene. 2003 May 29;22(22):3371-85
12776188
J Clin Oncol. 2003 Aug 1;21(15):2876-82
12885804
J Virol. 2004 Feb;78(4):1918-27
14747556
J Clin Oncol. 2004 Feb 1;22(3):399-402
14752065
J Exp Med. 2004 Apr 5;199(7):993-1003
15067035
Am J Surg Pathol. 2004 Nov;28(11):1401-16
15489644
Blood. 2005 Mar 15;105(6):2510-8
15572586
N Engl J Med. 2005 Mar 31;352(13):1317-23
15800227
J Clin Oncol. 2005 Jul 1;23(19):4372-80
15994147
Cancer Res. 2006 Jan 1;66(1):168-74
16397229
J Virol. 2006 Jul;80(14):7179-85
16809323
AIDS. 2006 Aug 1;20(12):1645-54
16868446
Cancer Cell. 2006 Aug;10(2):133-43
16904612
J Infect Dis. 2006 Oct 15;194(8):1078-88
16991082
Blood. 2007 Mar 1;109(5):2165-73
17082322
J Virol. 2007 Mar;81(5):2401-17
17151125
Oncologist. 2007 Jan;12(1):114-23
17227906
J Clin Invest. 2007 Apr;117(4):1019-28
17364023
J Natl Cancer Inst. 2007 Jun 20;99(12):962-72
17565153
J Clin Oncol. 2007 Aug 1;25(22):3350-6
17664482
Ann Intern Med. 2007 Dec 18;147(12):836-9
18087054
J Virol. 2008 Sep;82(17):8771-9
18579585
Transplantation. 2008 Sep 15;86(5):738-44
18791457
J Acquir Immune Defic Syndr. 2009 Feb 1;50(2):162-7
19131893
Ann Oncol. 2009 Apr;20(4):775-9
19179554
J Virol. 2010 May;84(10):5229-37
20219912
Cancer. 2010 Aug 15;116(16):3969-77
20564162
Clin Infect Dis. 2010 Aug 1;51(3):350-8
20583924
Blood. 2011 Jun 30;117(26):6977-86
21487108
J Virol. 2011 Oct;85(19):9877-86
21813606
Cancer Epidemiol Biomarkers Prev. 2011 Dec;20(12):2551-9
22109347
Blood. 2012 Mar 8;119(10):2228-33
22223822
J Acquir Immune Defic Syndr. 2012 Jun 1;60(2):150-7
22395672
Front Microbiol. 2012 Mar 02;3:73
22403576
J Clin Oncol. 2012 May 1;30(13):1476-83
22430271
Blood. 2012 May 31;119(22):5173-81
22490805
Curr Opin Oncol. 2012 Sep;24(5):495-505
22729151
Cancer Res. 2013 Apr 1;73(7):2235-46
23382046
Cell Host Microbe. 2013 Apr 17;13(4):429-40
23601105
Blood. 2013 Dec 19;122(26):4189-98
24174627
J Clin Oncol. 2014 Feb 10;32(5):409-14
24378415
J Clin Oncol. 2014 Feb 10;32(5):402-8
24378417
PLoS Pathog. 2013;9(12):e1003857
24385912
PLoS Pathog. 2014 Oct 09;10(10):e1004389
25299066
Blood. 2014 Dec 4;124(24):3544-52
25331113
PLoS Pathog. 2015 Mar 20;11(3):e1004771
25794275
Virus Res. 2015 Nov 2;209:39-44
25796211
Oncogene. 2016 Apr 7;35(14):1797-810
26119939
Int J Cancer. 2016 Jan 1;138(1):45-54
26175054
PLoS One. 2015 Aug 11;10(8):e0135560
26263384
J Virol. 2015 Oct 21;90(1):368-78
26491160
Clin Infect Dis. 2016 Mar 15;62(6):730-738
26658701
J Clin Oncol. 2016 Dec;34(34):4125-4131
27863194
Cancer. 1978 Dec;42(6):2626-30
728865
Blood. 1995 Aug 15;86(4):1276-80
7632932
N Engl J Med. 1995 May 4;332(18):1186-91
7700311
Science. 1994 Dec 16;266(5192):1865-9
7997879
Blood. 1996 Jul 15;88(2):645-56
8695812
J Clin Oncol. 1996 Aug;14(8):2353-64
8708728
AIDS. 1996 Jan;10(1):61-7
8924253
J Infect Dis. 1997 Jul;176(1):94-102
9207354
J Clin Oncol. 1997 Sep;15(9):3085-92
9294471
Blood. 1998 Feb 1;91(3):968-76
9446658
J Clin Oncol. 1998 Feb;16(2):683-91
9469358
J Clin Oncol. 1998 Mar;16(3):1112-21
9508198
N Engl J Med. 1998 Apr 2;338(14):948-54
9521982
J Clin Oncol. 1998 May;16(5):1736-42
9586886
J Clin Oncol. 1998 Jul;16(7):2445-51
9667262
Br J Cancer. 1998 Dec;78(11):1521-8
9836488